Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.45 |
| ▸ | PPARA | Q07869 | 9/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574319 | 0.90 | PPARD (0.49) | PPARDPPARAS1PR1S1PR5S1PR3 | |
| SCHEMBL3575828 | 0.89 | PPARD (0.42) | PPARDPPARAS1PR1HDAC1HDAC2 | |
| SCHEMBL3590124 | 0.85 | PPARD (0.41) | PPARDPPARA | |
| SCHEMBL3574790 | 0.85 | HRH3 (0.42) | PPARDPPARAHDAC1HDAC2HDAC6 | |
| SCHEMBL3585459 | 0.84 | PPARA (0.43) | PPARDPPARAHDAC1HDAC2HDAC6 | |
| SCHEMBL3575279 | 0.83 | HRH3 (0.46) | PPARDPPARA | |
| SCHEMBL3582912 | 0.82 | PPARA (0.46) | PPARDPPARA | |
| SCHEMBL3586967 | 0.81 | PPARD (0.37) | PPARDPPARA | |
| SCHEMBL13542113 | 0.79 | TSHR (0.42) | PPARDPPARAHDAC1HDAC2HDAC6 | |
| SCHEMBL3585140 | 0.79 | PPARA (0.47) | PPARDPPARAHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | PPARD 1213/4885PPARA 1138/4885S1PR1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.